

Recent events 2000 – 2006

Novartis accelerates production capacity of life-saving malaria treatment *Coartem* to 100 million treatment courses, up from 30 million in 2005. *Coartem* is the only pre-qualified, fixed-dose artemisinin-based combination therapy (ACT) and achieves cure rates of up to 95%. In September Novartis begins subsidizing *Coartem*, reducing the average treatment price by more than one-third to USD 1.00. **2006**

Novartis completes the divestment of Nutrition & Santé for USD 260 million to ABN AMRO Capital France.

Novartis and Alnylam Pharmaceuticals form a new collaboration to develop therapeutics for pandemic influenza treatment based on RNA interference (RNAi) technology.

Novartis completes the full acquisition of Chiron Corporation for USD 5.4 billion, creating the new Vaccines and Diagnostics Division.

Omnitrope receives European regulatory approval, the first approved under the European Union's new regulatory pathway for follow-on biological products.

The US Department of Health and Human Services (HHS) grants Novartis a contract worth up to USD 220 million to build a cell culture-based influenza vaccine production plant in North Carolina, recognizing Novartis as a leader in influenza vaccine development.

The Singapore-based Novartis Institute for Tropical Diseases (NITD) initiates research into the next generation of malaria medicines after receiving a USD 20 million grant from the Wellcome Trust, the Singapore Economic Development Board (EDB), and Medicines for Malaria Venture (MMV).

Novartis announces the acquisition of Sankyo Lifetech, expanding the presence of the Animal Health business in Japan.

Novartis begins work to create a new strategic biomedical R&D center in Shanghai, China. The center will become an integral part of the Group's global research and development network.

Novartis announces a definitive agreement to divest Medical Nutrition to Nestlé for USD 2.5 billion. This transaction was completed in 2007.

Recent events 2000 – 2006

Novartis acquires Hexal AG and Eon Labs, making Sandoz a world leader in generic pharmaceuticals, with the Hexal transaction completed in June and Eon Labs in July.

2005

The North American OTC product portfolio of Bristol-Myers Squibb is acquired, expanding Novartis presence in over-the-counter medicines with many strong brands.

Novartis and Alnylam Pharmaceuticals, Inc. create an alliance focused on the discovery of innovative therapeutics based on RNA interference (RNAi).

Interim data from the landmark IRIS trial shows that more than 90% of patients with a form of chronic myeloid leukemia (CML) taking *Gleevec/Glivec* were alive after five years of treatment.

The Novartis Institute for Tropical Diseases opens in Singapore with a focus on biomedical research for dengue fever and drug-resistant tuberculosis.

2004

Novartis acquires two generics companies: the Danish firm Durasacan A/S, from AstraZeneca plc, and Sabex Holdings Ltd., of Canada.

The Novartis Institutes for BioMedical Research (NIBR) announces a joint project with the Broad Institute of MIT and Harvard to decipher the genetic causes of type 2 diabetes. The project made its findings available to all scientists worldwide on the Web.

Sandoz is named as a division of the Novartis Group as of January 1, 2005.

The Novartis Foundation for Sustainable Development celebrates its 25th anniversary with a symposium on the right to health.

Several Novartis generic pharmaceutical businesses are unified under the name Sandoz.

2003

Novartis increases its investment in Roche Holding AG to just under one-third of Roche's voting shares, representing approximately 6% of Roche's total shares and equity securities.

Recent events 2000 – 2006

Lek Pharmaceuticals d.d., the Slovenian generic pharmaceuticals company, is acquired for USD 900 million. **2002**

Associated British Foods plc acquires the Food & Beverage business unit as part of a decision by Novartis to divest its Health & Functional Food business.

Novartis unifies and strengthens its global research network by creating the Novartis Institutes for BioMedical Research (NIBR), headquartered in the US.

The antimalarial drug *Coartem* is first made available to the World Health Organization (WHO) at cost. **2001**

Syngenta is created through the merger of the agribusiness units of Novartis and AstraZeneca. **2000**

Novartis American Depositary Shares (ADSs) are listed on the New York Stock Exchange (NYSE).